

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

February 13, 2024

Kimberlee C. Drapkin Chief Executive Officer Graphite Bio, Inc. 611 Gateway Blvd., Suite 120 San Francisco, CA 94080

> Re: Graphite Bio, Inc. Amendment No. 3 to Registration Statement on Form S-4 Exhibit Nos. 10.30, 10.45, and 10.46 Filed February 9, 2024 File No. 333-275919

Dear Kimberlee C. Drapkin:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Andrew Goodman, Esq.